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COST-EFFECTIVENESS OF A LIFESTYLE INTERVENTION FOR
HYPERTENSION: AN OPEN RANDOMISED CONTROLLED
TRIAL
Martikainen JA1, Kastarinen M2, Puska P3, Nissinen A3
1University of Kuopio, Kuopio, Finland, 2Kuopio University Hospital,
Kuopio, Finland, 3National Public Health Institute, Helsinki, Finland
Elevated blood pressure (BP) is a common chronic condition.
Hypertension is a signiﬁcant risk factor for cardiovascular dis-
eases (CVD) and mortality. In addition, its consequences are a
signiﬁcant burden to society due to hospital admissions, use of
anti-hypertensive drugs, sickness leaves, and disability pensions.
OBJECTIVE: To estimate the cost-effectiveness of systematic
health counselling in the treatment of hypertension in primary
health care. METHODS: A cost-effectiveness analysis was per-
formed alongside an open clinical trial, where 698 subjects aged
25–74 years with systolic BP (SBP) 140–179 mmHg and/or dias-
tolic BP (DBP) 90–109 mmHg or antihypertensive drug treat-
ment were randomised to intervention and usual care groups.
The intervention was provided by trained public health nurses,
who gave lifestyle counselling targeting weight reduction, restric-
tion in salt, alcohol and saturated fat consumption, and increas-
ing leisure time physical activity. Short-term effects in the BP
levels were extrapolated to obtain 10-year fatal CVD events by
using the SCORE risk function. Incremental cost-effectiveness
(ICER) was determined as cost per 1 mmHg reduction in SBP
and DBP levels, and cost per life-years saved (LYS). Uncertainty
was handled using a parametric Bayesian framework. RESULTS:
The absolute change in the BP levels was signiﬁcantly greater in
the intervention group among patients without antihypertensive
drug treatment compared to similar patients in the usual care
group (−2.4 mmHg in SBP and −2.0 mmHg in DBP). The differ-
ence in the BP reduction in patients with antihypertensive drug
treatment was not signiﬁcant between groups. For the patients
not receiving antihypertensive drugs ICERs were €60 per 
1 mmHg reduction in SBP and €72 per 1 mmHg reduction in
DBP, and €98,000 per LYS. CONCLUSIONS: The lifestyle coun-
selling in the primary care setting is a moderately cost-effective
method to treat patients to the treatment goals at least for
patients without previous antihypertensive drug treatment.
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CLINICAL EFFECTIVENESS OF BETALOC ZOC COMPARED 
TO METOPROLOL TARTRATE OR CARVEDILOL IN
HYPERTENSION TREATMENT
Kawalec P1, Borek E2
1Jagiellonian University, Kraków, Poland, 2Astra Zeneca Poland,
Warsaw, Poland
OBJECTIVES: To assess the clinical effectiveness of Betaloc
ZOC (metoprolol succinate), metoprolol tartrate or carvedilol in
a treatment of primary arterial hypertension. METHODS: Sys-
tematic review of published clinical trials selected in accordance
with Cochrane Collaboration guidelines was conducted to assess
effectiveness and safety of the drugs in hypertension treatment.
Systematic review was conducted in August 2005; Medline
(Pubmed) Cochrane and EMBASE were searched to ﬁnd relevant
clinical trials. Only randomized clinical trials with credibility
assessment of two or more points according to Jadad scale were
included in the systematic review. In case no clinical trials with
“head to head comparison” between metoprolol succinate and
metoprolol tartrate or carvedilol were found, indirect effective-
ness assessment with a common reference was done. Clinical
data was pooled with RevMan 4.2. RESULTS: Six relevant clin-
ical trials with direct comparison of metoprolol succinate and
metoprolol tartrate were found. Pooled clinical data on proba-
bility of diastolic pressure normalization (BP < 95 mmHg) in case
of Betaloc ZOC use compared to metoprolol tartrate revealed
insigniﬁcant trend favouring Betaloc ZOC (respectively 69.2%
vs. 63.4%); no signiﬁcant difference in safety proﬁle was shown
between the drugs (respectively 40.7% vs. 41.9%). Systematic
review revealed no randomized, “head to head comparison” clin-
ical trials with metoprolol succinate and carvedilol; indirect com-
parison of the drugs with atenolol as a common reference was
done to assess their clinical effectiveness. Indirect comparison
showed superiority of Betaloc ZOC over carvedilol in hyperten-
sion treatment (respectively: 81% vs 71.4%); no signiﬁcant dif-
ferences in safety proﬁle were revealed. CONCLUSIONS:
Betaloc ZOC use in place of metoprolol tartrate or carvedilol
lead to higher clinical effectiveness in primary arterial hyperten-
sion treatment.
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EFFECT OF ABSOLUTE REDUCTION IN LDL CHOLESTEROL
ON CARDIOVASCULAR EVENTS: DOES FINAL LDL
CHOLESTEROL ACHEIVED MATTER?
Rahilly CR1, Gaziano J2, Scranton R2
1Boston VA Health care System, Jamaica Plain, MA, USA, 2VA Boston
Health care System, Harvard Medical School, Boston, MA, USA
OBJECTIVE: A recent meta-regression of clinical trials of statins
demonstrated a linear relationship between magnitude of reduc-
tion of low-density lipoprotein cholesterol (LDL-C) and magni-
tude of cardiovascular risk reduction. We hypothesized that
magnitude of reduction of LDL-C would be roughly propor-
tional to degree of cardiovascular risk reduction, both for
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